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INTRODUCTION
The clinical treatment of patients with human im-
munodeficiency virus (HIV)-1 infection has been
advanced by the success of highly active antiretrovi-
ral therapy. The latest treatment guidelines recom-
mend regimen including efavirenz, a first-genera-
tion non-nucleoside reverse transcriptase inhibitor
(NNRTI), as one of the standard first-line regimen
(1). However, efavirenz use is limited by low genetic
barrier to resistance and central nervous system
toxity (2, 3). Therefore, new antiretroviral drugs,
which have long-term efficacy and good tolerabil-
ity, are required to continue effective therapy for
the treatment of HIV-1.
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Rilpivirine (TMC-278) is a second-generation
NNRTI that is high potent against both wild-type
and drug-resistant HIV-1 strains (4). Consequently,
rilpivirine is expected to treat therapy-experienced
patients who failed to use current drugs due to the
emergence of drug-resistant HIV mutants. In addi-
tion, rilpivirine shows a favourable safety profile (5-
7). The recommended dose of rilpivirine is 25 mg
(one tablet) once daily in combination with other
antiretroviral agents. No dose adjustment is required
in patients with moderate hepatic or renal impair-
ment. However, rilpivirine is primarily metabolized
by cytochrome P450 (CYP)3A. Therefore, co-ad-
ministration of rilpivirine and CYP3A inducer may
result in decreased plasma concentrations of rilpivi-
rine, loss of virologic response, and possible resis-
tance to rilpivirine. To avoid these risks, therapeu-
tic drug monitoring of rilpivirine is essential.
Else et al. (8) recently determined plasma rilpivi-
rine concentrations using liquid chromatography-
tandem mass spectrometry (LC-MS/MS). How-
ever, more simple and easy system to determine
plasma rilpivirine concentrations has been required.
Now we have a routine system, by which antiretrovi-
ral drug plasma concentrations are easily deter-
mined by HPLC (9). According to our preliminary
HPLC application, the sensitivity of LC-MS method
must at least be essential for quantification of plasma
rilpivirine. In this study, we intended to develop a
conventional method for determining plasma rilpivi-
rine concentrations by LC-MS.
MATERIALS AND METHODS
Chemicals and Reagents
Rilpivirine was supplied by Janssen Pharmaceu-
tica (Turnhoutseweg, Beerse, Belgium) and the
internal standard (IS), 6,7-Dimethyl-2,3-di (2-
pyridyl)-quinoxaline, was purchased from Sigma-
Aldrich (St Louis, MO, USA). Methanol, n -hexane,
ethyl acetate, and acetonitrile (Kanto Chemical,
Tokyo, Japan) were HPLC grade. Ammonium ace-
tate, EDTA and acetic acid were purchased from
Katayama Chemical (Osaka, Japan). Water was
deionized and osmosed using a Milli-Q system
(Millipore Corp., Bedford, MA, USA). All other
chemicals and solvents were of analytical grade.
Equipment
A Waters Alliance 2695 HPLC and a Micromass
ZQ-2000 MS (Waters Assoc., Milford, MA, USA),
controlled with MassLynx version 4.0 software, were
used for detection. The analytical column was a
SunFire C18 column (3.5 μm, 2.150 mm, Waters),
protected by a SunFire C18 Guard Column.
Chromatographic and mass spectrometric conditions
The mobile phase was a mixture of 0.1 mM
EDTA in 0.1% acetic acid (A), 100% acetonitrile (B)
and 100% methanol (C). An isocratic mobile phase
consisting of A-B-C (65 : 15 : 20) was used during
the first 2 min of the run, followed by a linear gra-
dient elution consisting of A-B-C (30 : 50 : 20) for
the next 8 min. The final conditions were maintained
for the final 5 min. The system was then reequili-
brated for an additional 25 min using the initial
conditions. The flow rate of the mobile phase was
0.2 ml/min, the column temperature was 40, and
the amount of injected sample was 5 μl.
The mass spectrometer was operated in positive
ion electrospray mode. The capillary sprayer volt-
age was 3.5 kV and the sample cone voltage was
30 V for both rilpivirine and the internal standard.
The source temperature was 120and the desolva-
tion temperature was 350. The desolvation and
cone gas flow-rates were set to 600 and 50 L/h,
respectively. The acquisition mass range is m/z
200-800 at 0.5 s per scan with a 0.1 s interscan de-
lay. All mass spectra are acquired in centroid mode.
Quantitative analysis, carried out in selected-ion
recording (SIR) mode, detected rilpivirine at m/z
367, and the IS, at m/z 313, all in the form of ions.
The quantitation calculations were performed using
analytical software, MassLynx version 4.0 (Waters).
Standard Solutions
Stock solutions of rilpivirine and the IS were pre-
pared by dissolving accurately weighed amounts of
each reference compound in water/ethanol (50 : 50,
v/v) to yield concentrations of 143.0 μg/ml of ril-
pivirine and 588.0 μg/ml of the IS. These stock so-
lutions were stored at -80and thawed on the day
of analysis. The stock solution was diluted in drug-
free plasma to yield rilpivirine concentrations of
18, 72, 143, 358 and 715 ng/ml.
Sample Preparation
Two milliliters of ethyl acetatate/n -hexane (50 :
50, v/v) containing the IS (177.5 ng/ml) and 1.0
ml of 0.2 M ammonium acetate were added to a
500 μl plasma sample prepared from peripheral
blood anticoagulated with heparin. The mixture was
vortexed for 5 min and then centrifuged at 3,500 g
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for 5 min. The upper layer was separated and evapo-
rated dry. The dried material was then dissolved in
50 μl of a mobile phase solution. Lastly, 5 μl of the
upper solution was injected into the LC-MS system.
The institutional review board of National Hospital
Organization Nagoya Medical Center approved this
study and each subject provided written informed
consent.
Validation
Inter- and intraday precision values using this
method were estimated by assaying control plasma
containing five different concentrations of rilpivirine
five times on the same day and on three separate
days to obtain the relative standard deviation (RSD).
The measured value was calculated as the peak area
ratio of rilpivirine to the internal standard. The ex-
traction recovery was determined by comparing the
peak areas obtained from the extracted samples in
plasma with those of direct injected standards, at
the same concentrations. The mean recoveries were
determined in triplicate. Accuracy was determined
as the percentage of the nominal concentration.
RESULTS
LC-MS Chromatograms
Figures 1A and B show selected-ion recording
chromatograms obtained from a spiked plasma sam-
ple containing 143.0 ng/ml of rilpivirine and 177.5
ng/ml of the IS. Under the described chroma-
tographic conditions, retention times were 5.3 min
for rilpivirine and 10.0 min for IS. Figures 1C and
D show chromatograms obtained from a blank
plasma sample. Assays performed on drug-free hu-
man plasma succeeded to show no interfering peaks
during the interested intervals of the retention times.
Figure 1D is the expanded figure of the baseline
part of Fig. 1B. These peaks did not affect the quan-
tification of the IS. Figures 1E and F show chroma-
tograms of a plasma sample from an HIV-1-infected
patient treated with rilpivirine. There were no in-
terfering peaks affecting quantification of rilpivirine
in this chromatogram. Anticoagulants of heparin and
EDTA did not hinder the selected-ion recording
chromatograms for rilpivirine and the IS.
Validation : Linearity, Precision, Accuracy and
Recovery
Calibration curves of rilpivirine appeared linear
in the concentration range of 18 to 715 ng/ml with
a correlation of 0.995.
Precision, accuracy, and recovery of our LC-MS
method are shown in Table 1. The selected con-
centration of rilpivirine covers the expected plasma
concentrations found in the patients. The RSDs
calculated for rilpivirine in the inter- and intraday
Figure 1. Selected- ion recording chromatograms for rilpivirine and the internal standard.
(A) and (B) were obtained from a spiked plasma containing 143 ng/ml of rilpivirine and 178 ng/ml of the internal standard (IS). (C)
and (D) were obtained from a blank plasma sample. (E) and (F) were obtained from a plasma sample from an HIV-1- infected pa-
tient on rilpivirine at 16 h after orally administration. (A), (C) and (E) were monitored with m/z 367. (B), (D) and (F) were moni-
tored with m/z 313. (C) and (D) are the expanded figures of the baselines in (A) and (B), respectively.
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assays ranged from 0.8 to 3.3%, which are similar
to values reported by LC-MS/MS method (8). Ac-
curacies ranged from 100.0 to 100.6%. Recoveries
from plasma ranged from 82.0 to 88.3%. These re-
sults indicate that this method achieves a high de-
gree of reproducibility and accuracy.
Clinical application
Figure 2 shows the distribution of plasma rilpivi-
rine concentrations in 6 Japanese HIV-1 infected
patients. Rilpivirine plasma concentrations were
measured at trough level (14-22 h after orally ad-
ministration). Mean rilpivirine plasma concentration
was 4922 ng/ml (n=6, range : 23-90 ng/ml). Ril-
pivirine has been just approved at May 2012 in Ja-
pan. This result is the first rilpivirine concentration
data for Japanese HIV-1 infected patients. These ril-
pivirine concentrations were similar to values re-
ported by foreign healthy volunteers (12).
DISCUSSION
In NNRTI-based regimens, efavirenz is recom-
mended as an initial combination regimen for
antiretroviral-naïve patients, because no regime has
proven superior to efavirenz-based regimens with
respect to virologic responses. However, efavirenz-
based regimens are associated with rash and central
nervous system adverse effects (1-3). Clinical trials
of rilpivirine (TMC-278) have showed the same ef-
ficacy compared with efavirenz, with a slightly in-
creased incidence of virological failures, but a more
favourable safety and tolerability profile (10, 11).
Therefore, rilpivirine can be an alternative NNRTI-
based regimen for antiretroviral therapy-naive pa-
tients infected with HIV-1.
Rilpivirine is a substrate of CYP3A4 and its phar-
macokinetics is likely to be modulated by inhibitors
and inducers of these enzymes. To manage these
drug interactions and ensure optimal drug efficacy,
monitoring plasma rilpivirine concentrations is es-
sential. For this purpose, we developed a method
for determining plasma rilpivirine concentrations
using LC-MS. The principal advantages of our
method are rapid liquid-liquid drug extraction from
plasma and use of an available IS, a commercial
compound. Validation showed our method was suc-
cessful in measuring plasma rilpivirine with high
precision and satisfactory RSD values. The rilpivi-
rine calibration curve was linear at the concentra-
tion range of 18 to 715 ng/ml, and the average ac-
curacy ranged from 100.0 to 100.6%. Both inter-
and intraday RSDs for rilpivirine were less than
3.3%, which is similar to previously reported values
by LC-MS/MS (8). Recovery of rilpivirine was more
than 82.0%. These results indicate our newly devel-
oped method achieves the same level of reproduci-
bility and accuracy as the LC-MS/MS method. As
plasma concentrations of rilpivirine are expected in
the 67 to 204 ng/ml range when rilpivirine is ad-
ministered at single dose of 25 mg for healthy vol-
unteers (12), our method successfully covers this
region with good precision and accuracy. In clini-
cal practice, mean rilpivirine plasma concentration
Table 1. Intraday and interday precision and accuracy for rilpivirine















18 18.10.2 1.0 18.00.4 2.4 100.31.0 85.11.3
72 72.31.4 1.9 72.02.3 3.3 100.41.9 82.03.7
143 143.73.0 2.1 143.93.1 2.2 100.52.1 87.60.6
358 360.22.9 0.8 357.85.2 1.5 100.60.8 88.37.2
715 715.08.6 1.2 716.36.1 0.8 100.01.2 84.08.6
RSD, relative standard deviation
MeansSD
Figure 2. Distribution of rilpivirine plasma concentrations in
6 Japanese HIV-1 infected patients.
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at trough was 49 ng/ml. This level compared fa-
vourably with trough concentrations of about 50-
80 ng/ml seen in ECHO and THRIVE trials (10,
11, 13).
In conclusion, our LC-MS method provides a con-
ventional, accurate and precise way to determine
rilpivirine in human plasma. This method can be
used in routine clinical application for HIV-1 infected
patients, and permits management of drug interac-
tions and toxicity for rilpivirine.
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